Vevo: scaling up in vivo discovery of cancer targets

Vevo is creating individual mice that model the tumor biology of hundreds of patients, dramatically scaling up in vivo target discovery while unraveling the connections between drug responses and the genetic backgrounds of individual patients.

Vevo Therapeutics Inc. launched In December 2022 with a $12 million seed round co-led by Wing Venture Capital and General Catalyst, and a mission to model patient diversity early in the drug discovery process, in a high-throughput in vivo system...